Paul Horstmeier - 09 Mar 2022 Form 4/A - Amendment Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Operating Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Issuer symbol: HCAT
Transactions as of: 09 Mar 2022
Net transactions value: -$450,652
Form type: 4/A - Amendment
Filing time: 08 Apr 2022, 17:36:12 UTC
Date Of Original Report: 11 Mar 2022
Previous filing: 03 Mar 2022
Next filing: 14 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$8,253	+521	+0.27%	$15.84	196,877	09 Mar 2022	Direct
transaction	HCAT	Common Stock	Options Exercise	$65,989	+4,166	+2.1%	$15.84	201,043	09 Mar 2022	Direct
transaction	HCAT	Common Stock	Sale	$519,665	-20,526	-10%	$25.32	180,517	09 Mar 2022	Direct	F1, F2, F3
transaction	HCAT	Common Stock	Sale	$5,229	-201	-0.11%	$26.02	180,316	09 Mar 2022	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-4,166	-9.5%	$0.000000	39,569	09 Mar 2022	Common Stock	4,166	$15.84	Direct	F5
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-521	-7.7%	$0.000000	6,248	09 Mar 2022	Common Stock	521	$15.84	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person in accordance with Rule 10b5-1.
F2	Due to a technical and administrative error, the original Form 4, filed on March 11, 2022, incorrectly included the sale of 2,482 shares of Common Stock by the Reporting Person that did not occur and was duplicative of the sale of such 2,482 shares of Common Stock that were previously reported.
F3	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $25.00 to $25.96, inclusive.
F4	Represents the weighted average sale price of the shares sold ranging from $26.00 to $26.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (3) and (4).
F5	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.
F6	25% of the 25,000 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.